Epstein Secrets

head...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, WBA Date: December 15, 2016 at 10:59:39 AM EST To: "Rich Kahn" Pd Reply-To: "Ens, Amanda" co The US team is out with their 2017 Year Ahead this morning ( top pick into the new year. ink) running through ALL sub-sectors with each analyst

has diminished (although will remain in pockets) but pipelines/growth remains. Ying’s top picks are CELG & REGN; Tazeen’s top picks are ACAD & RARE. Spec Pharma (-) — headwinds remain w/ Sumant’s top pick AGN given lower risk to reimbursement pressures & an underappreciated pipeline. Leverage & CF remain the

From: leffrey E. <[email protected]> To: "Ens, Amanda" •;: > Subject: Re: Preferreds, thoughts on fixed income, mandatory converts Date: Mon. OR Aug 2016 20:39:37 +0000 Inline-Images: image015.jpg: im

inue to like TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. rontler Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. Fifes earnings miss was due to a de

From: "Ens, Amanda" < 1:, To: "[email protected]" <[email protected]> Cc: Richard Kahn Subject: RE: Preferreds, thoughts on fixed income, mandatory converts

tinue to like TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks In Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a d

From: "Ens, Amanda" •fl• To: "jeevacationtantail.com" <[email protected]> Cc: Richard Kahn Subject: Prefermds, thoughts on fixed income, mandatory converts Date

tinue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAM reaffirming BUY after rontier reported its first post-Verizon assets merger results. FTR's ea nings miss was due to a dec

mages: image0Ol.png Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York. NY 10022 cc Begin forwarded message: From: -Ens, Amanda' •z > Subject: Allergen and Teva Date: July 28, 2016 at 9:08:09 AM EDT To: Richard Kahn ‹ > Rich, Regarding biotech, our traders mentioned they

inue to like TEVA's positioning In generic pharma where scale and product diversity are Increasingly Important. TEVA remains one of our top picks in Spec Pharma, $72 price objective (30% upside). Quick glance at TEVA 7% preferreds 905.50-907 vs $55.16. The Pfds yield 7.7% vs 2.47% in common giving yield ad

From: jeffrey E. <[email protected]> Sent: Monday, August 8, 2016 8:59 PM To: Ens, Amanda; Richard Kahn Subject: Re: Preferreds, thoughts on fixed income, mandatory converts lets buy 1 m each =div class="gmail_quote">On Mon, Aug 8, 201

inue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a

From: jeffrey E. <[email protected]> Sent: Tuesday, August 9, 2016 2:23 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory converts When will yours open?? On Tuesday, 9 August 2016,=Ens, Amanda < III /a» wro

inue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a

Sent: Tuesday, August 9 2016 1:38:24 PM From: "Ens, Amanda" Subject: RE: Preferreds, thoughts on fixed income, mandatory converts To: "Jeffrey E." <[email protected]>, Richard Kahn imacie001.0nq imag

inue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a

Amanda Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10

nue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a